Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
Thomas Jefferson University
Thomas Jefferson University
InSightec
Sunnybrook Health Sciences Centre
Universitat Politècnica de València
Universitat Politècnica de València
Universitat Politècnica de València
Centre Georges Francois Leclerc
Hospital del Rio Hortega
Novosibirsk State University
Lanzhou University Second Hospital
Hopital Nord Franche-Comte
Sichuan University
University of Manitoba
Asan Medical Center
European Organisation for Research and Treatment of Cancer - EORTC
Istituto Oncologico Veneto IRCCS
University of California, San Francisco
Hospital del Rio Hortega
University of Nebraska
Henry Ford Health System
Beijing Sanbo Brain Hospital
University of Ulm
Karolinska University Hospital
University of Erlangen-NĂźrnberg Medical School
University of Iowa
Brighton and Sussex University Hospitals NHS Trust
Massachusetts General Hospital
University Hospital Regensburg
Allina Health System
Egyptian Medical Syndicate
Case Comprehensive Cancer Center
Centre Hospitalier Universitaire, Amiens
Sheri Kashmir Institute of Medical Sciences
National Institutes of Health Clinical Center (CC)
University of Wisconsin, Madison
University of California, San Francisco
Swiss Cancer Institute
Technische Universität Dresden
Alliance for Clinical Trials in Oncology
Eisai Inc.
Washington University School of Medicine
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
University Hospital, Lille
University of Pisa
Rockefeller University
University of Miami
Brigham and Women's Hospital
Wake Forest University Health Sciences
Eisai Inc.